Lyra Therapeutics

General Information


We are a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat, or ENT, diseases. Our proprietary technology platform, XTreo, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. Our initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

Employees: 34
Founded: 2005
Contact Information
Address 480 Arsenal Way, Watertown, MA 02472, US
Phone Number (617) 393-4600
Web Address
View Prospectus: Lyra Therapeutics
Financial Information
Market Cap $198.4mil
Revenues $0 mil (last 12 months)
Net Income $-16.3 mil (last 12 months)
IPO Profile
Symbol LYRA
Exchange NASDAQ
Shares (millions): 3.5
Price range $16.00 - $16.00
Est. $ Volume $56.0 mil
Manager / Joint Managers BofA Securities/ Jefferies/ William Blair
CO-Managers BTIG
Expected To Trade: 5/1/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change